-
Although regular aspirin use reduces the risk for colorectal adenoma formation as shown in previous randomized-controlled trials, the protective effect now seems to be greatest at substantially higher doses (> 14 standard tablets/week) than currently recommended for cardiovascular prophylaxis.
-
The FDA has approved a combination product of amlodipine and atrovastatin for the treatment of patients with comorbid hypertension and hypercholesterolemia.
-
The ECG shown in the Figure was obtained in the emergency department (ED) from a 61-year-old woman with a history of significant hypertension. She was alert, oriented, and not in acute distress at the time this tracing was recorded, although she was markedly hypertensive and experiencing some chest pain. No prior ECG was available. The patient was treated in the ED with several doses of Adenosine and eventually converted to sinus rhythm. Your thoughts on the rhythm and the management?
-
The NIH has halted the estrogen-alone wing of the Womens Health Initiative a year before its scheduled end.
-
In this randomized, controlled trial, European investigators looked at the role of vasopressin in treating out-of-hospital cardiac arrest. Although the study did not show any benefit of using vasopressin when compared to epinephrine in terms of survival to hospital, this study nonetheless makes a weak argument to use vasopressin in cardiac arrest patients with asystole.
-
This article points out the disadvantages of partial DNR ordersfor both clinicians and patientsand offers clear steps for mitigating the problem by developing a supplemental patient care plan for patients who are less than full code.
-
-
SYNERGY: The superior yield of the new Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors trial was presented by Dr. Kenneth Mahaffey and colleagues; WATCH: The Warfarin and Antiplatelet Trial in Chronic Heart failure was presented by Barry Massie, MD, from San Francisco.
-
Metabolic syndrome, but not obesity alone, was associated with a higher risk of cardiovascular events. The presence of MS in individuals with angiographic CAD at study entry substantially increased the likelihood of death and major adverse cardiovascular events.
-
The NIH has halted the estrogen-alone wing of the Womens Health Initiative a year before its scheduled end.